TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris
Brief Summary: This study will provide data on the addition of narrow band ultra violet B (nbUVB) phototherapy to participants who have not shown an excellent response to three months of etanercept.


Options:
A: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Non-systemic treatment.; Type: ACTIVE_COMPARATOR; Interventions: Device: UVB Phototherapy, Other: Topical treatment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: DEVICE; Name: UVB Phototherapy; Assigned to Arm(s): Non-systemic treatment. | Intervention Type: OTHER; Name: Topical treatment; Assigned to Arm(s): Non-systemic treatment.
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 2 mL form; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 2 mL form | Arm Label: Secukinumab 1 mL form; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab 1 mL form | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 2 mL form; Assigned to Arm(s): Secukinumab 2 mL form | Intervention Type: DRUG; Name: Secukinumab 1 mL form; Assigned to Arm(s): Secukinumab 1 mL form
C: Arm Label: Induction Single Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Induction Monthly Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Induction Early Loading Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Placebo Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): Induction Single Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Monthly Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Early Loading Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Dose
D: Arm Label: Part 1 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Part 2 - Etanercept and nbUVB; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Device: nbUVB | Arm Label: Part 2 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Part 1 - Etanercept, Part 2 - Etanercept, Part 2 - Etanercept and nbUVB | Intervention Type: DEVICE; Name: nbUVB; Assigned to Arm(s): Part 2 - Etanercept and nbUVB

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multi-centre, Prospective Study Comparing Best Medical Treatment Versus Best Medical Treatment Plus Renal Artery Stenting in Patients With Hemodynamically Relevant Atherosclerotic Renal Artery Stenosis
Brief Summary: The clinical investigation is a prospective, international, multi-centre, randomized (1:1) trial with follow ups at 2, 6, 12 months and 3 years.

The purpose of the study is to evaluate the clinical impact of percutaneous transluminal renal artery stenting (PTRAS) on the impaired renal function measured by the estimated Glomerular Filtration Rate (eGFR) in patients with hemodynamically significant atherosclerotic renal artery stenosis (ARAS).


Options:
A: Arm Label: STN; Type: EXPERIMENTAL; Interventions: Device: Dynamic Renal Stent plus Best Medical Treatment | Arm Label: BMT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Best Medical Treatment | Intervention Type: DEVICE; Name: Dynamic Renal Stent plus Best Medical Treatment; Assigned to Arm(s): STN | Intervention Type: DRUG; Name: Best Medical Treatment; Assigned to Arm(s): BMT
B: Arm Label: Optimal Medical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atacand/HCT, Caduet | Arm Label: Stenting; Type: EXPERIMENTAL; Interventions: Procedure: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting) | Intervention Type: DRUG; Name: Atacand/HCT, Caduet; Assigned to Arm(s): Optimal Medical Therapy | Intervention Type: PROCEDURE; Name: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting); Assigned to Arm(s): Stenting
C: Intervention Type: DEVICE; Name: Renal artery stent; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Angiographic renal revascularization; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HIV/Sexually Transmitted Disease (STD) Prevention Interventions for Black Adolescents
Brief Summary: This study will develop and evaluate the effectiveness of culturally appropriate HIV/sexually transmitted disease risk-reduction interventions in reducing sexual risk behavior among young African-American adolescents.


Options:
A: Arm Label: Traditional Prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Traditional Prevention | Arm Label: Web-based Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based Prevention | Intervention Type: BEHAVIORAL; Name: Traditional Prevention; Assigned to Arm(s): Traditional Prevention | Intervention Type: BEHAVIORAL; Name: Web-based Prevention; Assigned to Arm(s): Web-based Prevention
B: Arm Label: Alternative SoF; Type: EXPERIMENTAL; Interventions: Other: Alternative summary of findings table format | Arm Label: Current SoF; Type: ACTIVE_COMPARATOR; Interventions: Other: Current summary of findings table format | Intervention Type: OTHER; Name: Alternative summary of findings table format; Assigned to Arm(s): Alternative SoF | Intervention Type: OTHER; Name: Current summary of findings table format; Assigned to Arm(s): Current SoF
C: Arm Label: Abstinence-only; Type: EXPERIMENTAL; Interventions: Behavioral: Abstinence-only HIV/STD risk-reduction intervention | Arm Label: Safer-sex only; Type: EXPERIMENTAL; Interventions: Behavioral: Safer-sex-only HIV/STD risk-reduction intervention | Arm Label: Comprehensive-long; Type: EXPERIMENTAL; Interventions: Behavioral: Long comprehensive HIV/STD risk-reduction intervention | Arm Label: Comprehensive-short; Type: EXPERIMENTAL; Interventions: Behavioral: Short comprehensive HIV/STD risk-reduction intervention | Arm Label: Health-promotion control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health promotion control intervention | Intervention Type: BEHAVIORAL; Name: Abstinence-only HIV/STD risk-reduction intervention; Assigned to Arm(s): Abstinence-only | Intervention Type: BEHAVIORAL; Name: Safer-sex-only HIV/STD risk-reduction intervention; Assigned to Arm(s): Safer-sex only | Intervention Type: BEHAVIORAL; Name: Long comprehensive HIV/STD risk-reduction intervention; Assigned to Arm(s): Comprehensive-long | Intervention Type: BEHAVIORAL; Name: Short comprehensive HIV/STD risk-reduction intervention; Assigned to Arm(s): Comprehensive-short | Intervention Type: BEHAVIORAL; Name: Health promotion control intervention; Assigned to Arm(s): Health-promotion control
D: Arm Label: High reward; Type: EXPERIMENTAL; Interventions: Behavioral: Cash reward | Arm Label: Low reward; Type: EXPERIMENTAL; Interventions: Behavioral: Cash reward | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cash reward; Assigned to Arm(s): High reward, Low reward

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Multicenter Comparison of Balloon Angioplasty and the Cypher Selecttm + Coronary and Infrapopliteal Stent in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease
Brief Summary: The primary objective of this study is to compare the performance of the CYPHER SELECTTM + Sirolimus-eluting Balloon-expandable Coronary and Infrapopliteal Stent over balloon angioplasty in de novo and restenotic native below the knee tibioperoneal, anterior and/or posterior tibial and/or peroneal arterial lesions in a prospective, multicenter, randomized clinical study.


Options:
A: Arm Label: balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: balloon angioplasty | Arm Label: Drug eluting stent; Type: EXPERIMENTAL; Interventions: Device: drug eluting stent | Intervention Type: DEVICE; Name: balloon angioplasty; Assigned to Arm(s): balloon angioplasty | Intervention Type: DEVICE; Name: drug eluting stent; Assigned to Arm(s): Drug eluting stent
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Implantation of YUKON Sirolimus-eluting Stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Implantation of YUKON Stent (uncoated) | Intervention Type: DEVICE; Name: Implantation of YUKON Sirolimus-eluting Stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Implantation of YUKON Stent (uncoated); Assigned to Arm(s): 2
C: Arm Label: Astron Pulsar Stent; Type: EXPERIMENTAL; Interventions: Device: Astron Pulsar Stent | Arm Label: PTA alone; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA alone | Intervention Type: DEVICE; Name: Astron Pulsar Stent; Assigned to Arm(s): Astron Pulsar Stent | Intervention Type: DEVICE; Name: PTA alone; Assigned to Arm(s): PTA alone
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: PTA with placement of paclitaxel-eluting stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA | Intervention Type: DEVICE; Name: PTA with placement of paclitaxel-eluting stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: PTA; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo Controlled, Parallel Group 24 Week Study to Assess the Efficacy and Safety of BI 1356 (5 mg) in Combination With 30 mg Pioglitazone (Both Administered Orally Once Daily), Compared to 30 mg Pioglitazone Plus Placebo in Drug Naive or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control.
Brief Summary: The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (Linagliptin) (5 mg / once daily) compared to placebo given for 24 weeks as initial combination therapy with pioglitazone 30 mg in patients with type 2 diabetes mellitus with insufficient glycaemic control.


Options:
A: Arm Label: BI 1356 (5 mg); Type: EXPERIMENTAL; Interventions: Drug: Linagliptin + pioglitazone (30 mg) | Arm Label: Placebo matching BI 1356 5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo + pioglitazone (30 mg) | Intervention Type: DRUG; Name: placebo + pioglitazone (30 mg); Assigned to Arm(s): Placebo matching BI 1356 5 mg | Intervention Type: DRUG; Name: Linagliptin + pioglitazone (30 mg); Assigned to Arm(s): BI 1356 (5 mg)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: sitagliptin, Drug: open-label metformin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: glimepiride, Drug: open-label metformin | Intervention Type: DRUG; Name: sitagliptin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: glimepiride; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: open-label metformin; Assigned to Arm(s): 1, 2
C: Arm Label: albiglutide; Type: EXPERIMENTAL; Interventions: Biological: albiglutide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Arm Label: albiglutide up-titration; Type: EXPERIMENTAL; Interventions: Biological: albiglutide uptitration | Intervention Type: BIOLOGICAL; Name: albiglutide; Assigned to Arm(s): albiglutide | Intervention Type: BIOLOGICAL; Name: albiglutide uptitration; Assigned to Arm(s): albiglutide up-titration | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin | Arm Label: Placebo/Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Sitagliptin | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Placebo/Sitagliptin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Once-Weekly Exenatide Long-Acting Release and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea
Brief Summary: The purpose of this study is to compare the effects of 2.0 mg exenatide once weekly and insulin glargine, titrated to glucose targets using the algorithm described by Yki- Järvinen et al.(2007), with respect to glycemic improvements, body weight, fasting lipids, safety, and tolerability.


Options:
A: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: exenatide once weekly, Drug: placebo tablet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: sitagliptin, Drug: placebo once weekly | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone, Drug: placebo once weekly | Intervention Type: DRUG; Name: exenatide once weekly; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sitagliptin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo tablet; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo once weekly; Assigned to Arm(s): 2, 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Exenatide Once Weekly | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine | Intervention Type: DRUG; Name: Exenatide Once Weekly; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): 2
D: Arm Label: Lira 0.6 + Met; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: metformin, Drug: placebo | Arm Label: Lira 1.2 + Met; Type: EXPERIMENTAL; Interventions: Drug: metformin, Drug: placebo, Drug: liraglutide | Arm Label: Lira 1.8 + Met; Type: EXPERIMENTAL; Interventions: Drug: metformin, Drug: placebo, Drug: liraglutide | Arm Label: Met Mono; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin, Drug: placebo | Arm Label: Met + Glim; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin, Drug: glimepiride, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 0.6 + Met | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met, Met + Glim, Met Mono | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Met + Glim | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met, Met Mono | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Met + Glim, Met Mono | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 + Met | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 + Met

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiac Rehabilitation in Advanced aGE: EXercise TRaining and Active Follow-up, a Randomised Controlled Trial. CR-AGE EXTRA Trial
Brief Summary: The goal of this trial is to assess the medium- (6 months) and long-term (12 months) effects of a Home-Based exercise program after in-Hospital comprehensive Cardiac Rehabilitation (CR) - as compared with usual care - on exercise capacity, health-related quality of life and health care services utilization, in patients (pts) older than 75 years after recent acute coronary syndromes or cardiac surgery.


Options:
A: Arm Label: Women-Only Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Co-ed Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Home-Based Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Intervention Type: BEHAVIORAL; Name: Cardiac Rehabilitation; Assigned to Arm(s): Co-ed Cardiac Rehabilitation, Home-Based Cardiac Rehabilitation, Women-Only Cardiac Rehabilitation
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Rehabilitation in institution | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation at home, Behavioral: Out-patient rehabilitation at the hospital | Intervention Type: BEHAVIORAL; Name: Rehabilitation in institution; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Rehabilitation at home; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Out-patient rehabilitation at the hospital; Assigned to Arm(s): 2
C: Arm Label: A; Type: OTHER; Interventions: Other: A: Home-Based exercise after Cardiac Rehabilitation | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: A: Home-Based exercise after Cardiac Rehabilitation; Assigned to Arm(s): A
D: Arm Label: UC; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: vCRP; Type: EXPERIMENTAL; Interventions: Behavioral: vCRP | Intervention Type: BEHAVIORAL; Name: vCRP; Assigned to Arm(s): vCRP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiac Rehabilitation in Advanced aGE: EXercise TRaining and Active Follow-up, a Randomised Controlled Trial. CR-AGE EXTRA Trial
Brief Summary: The goal of this trial is to assess the medium- (6 months) and long-term (12 months) effects of a Home-Based exercise program after in-Hospital comprehensive Cardiac Rehabilitation (CR) - as compared with usual care - on exercise capacity, health-related quality of life and health care services utilization, in patients (pts) older than 75 years after recent acute coronary syndromes or cardiac surgery.


Options:
A: Arm Label: Cardio fit; Type: EXPERIMENTAL; Interventions: Behavioral: CardioFit | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CardioFit; Assigned to Arm(s): Cardio fit
B: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone text message | Arm Label: No Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mobile phone text message; Assigned to Arm(s): Experimental
C: Arm Label: A; Type: OTHER; Interventions: Other: A: Home-Based exercise after Cardiac Rehabilitation | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: A: Home-Based exercise after Cardiac Rehabilitation; Assigned to Arm(s): A
D: Arm Label: Weight Loss; Type: EXPERIMENTAL; Interventions: Other: Weight Loss | Arm Label: Interval Training; Type: EXPERIMENTAL; Interventions: Other: Interval Training | Intervention Type: OTHER; Name: Interval Training; Assigned to Arm(s): Interval Training | Intervention Type: OTHER; Name: Weight Loss; Assigned to Arm(s): Weight Loss

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's Disease
Brief Summary: This clinical trial is designed to evaluate the safety and potential efficacy of Xyrem for the treatment of excessive daytime sleepiness (EDS) and nocturnal sleep disturbance in patients with mild to moderate Parkinson's Disease (PD).


Options:
A: Arm Label: Early Pramipexole; Type: EXPERIMENTAL; Interventions: Drug: pramipexole | Arm Label: Delayed Pramipexole; Type: EXPERIMENTAL; Interventions: Drug: pramipexole | Intervention Type: DRUG; Name: pramipexole; Assigned to Arm(s): Delayed Pramipexole, Early Pramipexole
B: Arm Label: Xyrem in Parkinson disease; Type: EXPERIMENTAL; Interventions: Drug: sodium oxybate | Intervention Type: DRUG; Name: sodium oxybate; Assigned to Arm(s): Xyrem in Parkinson disease
C: Arm Label: Methylphenidate 0.4 mg/kg TID followed by placebo TID; Type: EXPERIMENTAL; Interventions: Drug: methylphenidate | Arm Label: Placebo TID followed by methylphenidate 0.4 mg/kg TID; Type: EXPERIMENTAL; Interventions: Drug: methylphenidate | Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): Methylphenidate 0.4 mg/kg TID followed by placebo TID, Placebo TID followed by methylphenidate 0.4 mg/kg TID
D: Arm Label: occupational therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Occupational Therapy | Arm Label: No occupational therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Occupational Therapy; Assigned to Arm(s): occupational therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Global Randomized Prospective Study of Intensive Medical Management of Type 2 Diabetes, With and Without Gastric Bypass Surgery
Brief Summary: The present study is the first stage of a research program whose ultimate goal is to conduct a randomized clinical trial involving type 2 diabetics with BMI from 30.0 to 39.9 kg/m2. This program will determine the relative effectiveness of RYGB combined with intensive medical management (IMM), versus IMM alone, in reducing CVD event rates and mortality in patients with poorly controlled diabetes. IMM will include rigorous lifestyle modification for weight loss and stepped pharmacologic treatment for diabetes and other CVD risk factors. The proposed study is a randomized trial which will provide an assessment of the efficacy of treatment, in reducing CVD risk factors and also assessing the feasibility, cost, and safety of a larger trial.


Options:
A: Arm Label: GBP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Bariatric surgery: Gastric bypass | Arm Label: BPD 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Bariatric surgery: Bilio-pancreatic diversion | Arm Label: Med Ter3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: anti-diabetic drugs and behavioral suggestions | Intervention Type: PROCEDURE; Name: Bariatric surgery: Gastric bypass; Assigned to Arm(s): GBP | Intervention Type: PROCEDURE; Name: Bariatric surgery: Bilio-pancreatic diversion; Assigned to Arm(s): BPD 2 | Intervention Type: BEHAVIORAL; Name: anti-diabetic drugs and behavioral suggestions; Assigned to Arm(s): Med Ter3
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: intensive medical management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: RYGB & IMM | Intervention Type: OTHER; Name: intensive medical management; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: RYGB & IMM; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic operation Sleeve Gastrectomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic operation Roux-en-Y Gastric bypass | Intervention Type: PROCEDURE; Name: laparoscopic operation Sleeve Gastrectomy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: laparoscopic operation Roux-en-Y Gastric bypass; Assigned to Arm(s): 2
D: Arm Label: Bariatric surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Bariatric surgery | Arm Label: Intensive lifestyle intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive lifestyle intervention | Intervention Type: PROCEDURE; Name: Bariatric surgery; Assigned to Arm(s): Bariatric surgery | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle intervention; Assigned to Arm(s): Intensive lifestyle intervention

Answer: B